Global Organs-on-chips Market Size By Type (Liver-on-a-chip, Kidney-on-a-chipLung-on-a-chip), By Application (Physiological Model Development, Drug Discovery), By Region, And Segment Forecasts, 2023 t...

The Global Organs-on-Chips Market was valued at USD 105.7 million in 2023 and is projected to surpass USD 384.6 million by 2031, growing at a CAGR of 17.4% during the forecast period from 2023 to 2031. Organs-on-chips (OoCs) are microfluidic cell culture devices that simulate the activities, mechanics, and physiological response of entire organs. The rising demand for alternative testing methods to animal models, growing investments in pharmaceutical R&D, and technological advancements in microengineering are the major drivers fueling the market’s expansion.

The technology offers a revolutionary approach to studying human physiology and disease, as well as drug development, by providing more accurate and ethical platforms for toxicity testing and disease modeling.

Drivers:

1. Increasing Demand for Animal-Free Testing Models: Growing ethical concerns and regulatory restrictions related to animal testing have driven pharmaceutical and cosmetic companies to adopt organs-on-chips technology, which offers reliable human-based test results.

2. Rapid Advancements in Microfluidics and Tissue Engineering: Continuous innovation in microfabrication, biomaterials, and stem cell technology is enhancing the fidelity and functionality of OoCs, improving their viability for complex disease modeling and drug screening.

3. Expansion of Personalized Medicine: Organs-on-chips allow patient-specific cell lines to be tested, creating potential for personalized treatment plans and significantly reducing trial-and-error methods in medication.

Restraints:

1. High Cost and Technical Complexity: OoC devices require advanced fabrication techniques, multidisciplinary expertise, and high development costs, which may limit adoption among smaller biotech firms and academic institutions.

2. Limited Standardization and Regulatory Frameworks: The lack of standardized protocols and regulatory guidelines for validation and commercialization of these systems poses a challenge for widespread acceptance, especially in clinical settings.

Opportunity:

1. Rising R&D Investment in Drug Discovery: Pharmaceutical and biotechnology firms are increasingly investing in novel tools like OoCs to reduce R&D costs, shorten drug development timelines, and increase the success rate of clinical trials.

2. Emerging Applications in Infectious Diseases and Oncology: Organs-on-chips are gaining traction in replicating tumor microenvironments and studying viral infections, offering new opportunities in oncology and infectious disease research.

3. Government Initiatives Supporting Alternative Testing Models: Various government agencies and non-profits are supporting the adoption of animal-free testing alternatives, including OoCs, which boosts market growth potential.

Market by System Type Insights:

The Liver-on-a-chip segment held the largest revenue share in 2023, owing to its critical role in drug metabolism and toxicity screening. Pharmaceutical companies widely use liver models to assess hepatotoxicity early in the drug development process. However, the Heart-on-a-chip and Lung-on-a-chip segments are expected to grow rapidly due to increasing cardiovascular and respiratory disease research and drug screening needs.

Market by End-use Insights:

Pharmaceutical & Biotechnology Companies emerged as the largest end-user segment in 2023, accounting for over 45% of the market share. These entities rely heavily on organs-on-chips for preclinical drug testing, reducing time and costs associated with traditional testing models. The Academic and Research Institutes segment is also witnessing substantial growth, driven by collaborations with industry and funding for innovative bioengineering research.

Market by Regional Insights:

North America dominated the global organs-on-chips market in 2023 due to robust healthcare infrastructure, extensive R&D activities, and the presence of major market players. Meanwhile, Asia-Pacific is poised to be the fastest-growing region during the forecast period. Countries like China, Japan, and South Korea are investing heavily in biotechnology research and expanding their capabilities in organ-on-chip technology development.

Competitive Scenario:

Key players operating in the Global Organs-on-Chips Market include:

Emulate Inc.

CN Bio Innovations

Mimetas B.V.

TissUse GmbH

AxoSim Inc.

Nortis Inc.

Hesperos Inc.

InSphero AG

These companies are focusing on collaborations with pharmaceutical giants, government research institutions, and technology upgrades to scale their platforms. For instance:

In 2023, Emulate Inc. launched a new customizable organ-on-chip platform for rare disease research.

In 2024, Mimetas B.V. partnered with a major pharma firm to accelerate screening of immuno-oncology therapeutics using its gut-on-a-chip platform.

In 2025, Hesperos Inc. announced a breakthrough in creating multi-organ systems for integrated pharmacokinetic and toxicology studies.

Scope of Work – Global Organs-on-Chips Market

Report Metric Details

Market Size (2023) USD 105.7 million

Projected Market Size (2031) USD 384.6 million

CAGR (2023–2031) 17.4%

Key Segments System Type (Liver, Lung, Heart, Kidney), End-Use (Pharma & Biotech, Academic & Research Institutes, Others), Region

Growth Drivers Demand for animal-free testing, rise in R&D, microengineering advancements

Opportunities Oncology & infectious disease research, personalized medicine, government support

Key Market Developments:

2023: CN Bio Innovations introduced a next-generation liver-on-chip platform for enhanced drug metabolism prediction.

2024: TissUse GmbH developed a two-organ chip system integrating liver and intestine tissues, facilitating complex ADME (absorption, distribution, metabolism, excretion) studies.

2025: Nortis Inc. secured funding to expand its kidney-on-chip research for early-stage nephrotoxicity screening.

FAQs:

1) What is the current market size of the Global Organs-on-Chips Market?

The market was valued at USD 105.7 million in 2023.

2) What is the major growth driver of the Global Organs-on-Chips Market?

The increasing need for animal-free testing alternatives and the growth in pharmaceutical R&D are key drivers.

3) Which is the largest region during the forecast period in the Global Organs-on-Chips Market?

North America is expected to remain the largest region through 2031.

4) Which segment accounted for the largest market share in the Global Organs-on-Chips Market?

The Liver-on-a-chip segment held the largest share in 2023.

5) Who are the key market players in the Global Organs-on-Chips Market?

Key players include Emulate Inc., CN Bio Innovations, Mimetas B.V., TissUse GmbH, and Hesperos Inc.